Compare AbCellera Biologics Inc (ABCL) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? AbCellera Biologics Inc trades at $10.54 (market cap $3.17B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.94 (market cap $79.36B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 25× AbCellera Biologics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.22% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MDLZ | |
|---|---|---|
Market Cap | $3.17B | $79.36B |
Sector | Health | Consumer Staples |
52-Week High | $10.36 | $64.99 |
52-Week Low | $2.78 | $51.51 |
Enterprise Value | $2.77B | $99.70B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
MDLZ trades at $61.99, up 0.75% today, with a bullish technical signal from moving averages and support at $61. The company reported Q2 2026 EPS of $0.73, beating estimates, and raised its organic sales outlook. Revenue grew to $38.54B in 2025, though net income margin declined to 6.36%. Analyst consensus is strongly bullish with a $70.50 price target.
Outlook is positive due to earnings beats and emerging market growth, but risks include margin pressure and high P/E of 37.75. Institutional activity is mixed, with some firms increasing stakes while others reduced holdings. The stock offers upside to target but faces execution risks in a competitive consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
